Results 11 to 20 of about 616,145 (212)

pTNM System in Non Small Cell Lung Carcinoma

Indonesian Journal of Cancer, 2008
Prognosis karsinoma paru berhubungan dengan berbagai macam faktor, antara lain : usia, jenis kelamin, ukuran tumor, staging, jenis sel dan derajat diferensiasi, invasi kepembuluh darah, dinding dada, efusi pleura, adanya jaringan ikat, keterlibatan KGB ...
Heriawaty Hidajat, Sutjahjo Endarjo, Ruth E Sembiring, Aziza Icksan, Elisna Syahrudin, Agung Wibawanto   +5 more
doaj   +1 more source

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. [PDF]

PLoS ONE, 2011
Squamous cell lung carcinomas account for approximately 25% of new lung carcinoma cases and 40,000 deaths per year in the United States. Although there are multiple genomically targeted therapies for lung adenocarcinoma, none has yet been reported in ...
Amit Dutt, Alex H Ramos, Peter S Hammerman, Craig Mermel, Jeonghee Cho, Tanaz Sharifnia, Ajit Chande, Kumiko Elisa Tanaka, Nicolas Stransky, Heidi Greulich, Nathanael S Gray, Matthew Meyerson   +11 more
doaj   +1 more source

The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung [PDF]

, 2018
Introduction: Because small-cell lung carcinomas (SCLC) are seldom resected, human materials for study are limited. Thus, genetically engineered mouse models (GEMMs) for SCLC and other high-grade lung neuroendocrine (NE) carcinomas are crucial for ...
Berns, Anton, Brambilla, Elisabeth, Farago, Anna F., Gazdar, Adi F., Jacks, Tyler E., Johnson, Jane E., Linnoila, R. Ilona, MacPherson, David, McFadden, David Glenn, Sage, Julien, Savage, Trisha K., Travis, William D.   +11 more
core   +1 more source

Predictive testing in non-small cell lung carcinoma

Klinicka onkologie, 2021
Predictive testing is a crucial part of the complete diagnostic process of non-small cell lung cancer (NSCLC) and a necessary requirement in order to determine proper course of treatment. However, the possibilities of testing and the spectrum of examined markers are quickly evolving as a result of the progress in diagnostic and therapeutic ...
P, Dundr, R-, Matěj, K, Němejcová, M, Bártů, I, Stružinská   +4 more
openaire   +2 more sources

Influence of ABO blood group on susceptibility to different pathological types of lung cancer: a retrospective study

World Journal of Surgical Oncology, 2022
Purpose Current research has shown a link between ABO blood group and many diseases. The purpose of this study aimed to investigate the influence of the ABO blood group on the risk of developing different pathological types of lung cancer.
Haotian Yang, Xianjun Zeng, Yu Zhang, Weilai Tong, Geliang Yao, Chunyu Lan, Jiaming Liu, Zhili Liu, Nanshan Zhong   +8 more
doaj   +1 more source

Overexpression of the non-coding SOX2OT variants 4 and 7 in lung tumors suggests an oncogenic role in lung cancer [PDF]

, 2016
Despite the advances in cancer therapy, lung cancer still remains the most leading cause of cancer death worldwide. The long non-coding RNAs (lncRNAs) are recently introduced as novel regulators of human cancers. SOX2 overlapping transcript (SOX2OT) is a
Ghanei, M., Mowla, S.J., Saghaeian Jazi, M., Samaei, N.M., Shadmehr, M.B.   +4 more
core   +1 more source

Durable response to durvalumab‐based immunochemotherapy in small‐cell lung carcinoma transformation from EGFR‐mutant non–small cell lung cancer: A case report

Thoracic Cancer, 2022
Combined small‐cell lung carcinoma (C‐SCLC) is small‐cell lung carcinoma (SCLC) with added non–small‐cell morphology. We report a case of epidermal growth factor receptor (EGFR) mutation‐positive C‐SCLC in an 84‐year‐old patient with metastatic brain ...
Yu‐Chung Li
doaj   +1 more source

Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients [PDF]

, 2015
There is a clinical need for reliable biomarkers for lung cancer that permit early diagnosis of the disease and provide prediction of histological phenotype.
AG Serrano, AM Fiorenza, Andrew W. Fogarty, CH Oak, D Kong, David A. Barrett, David R. Baldwin, E Wojcik, GL May, H Ulmer, H Yang, Helen L. Barr, J Castro de, J Chee, J Dong, J Liu, JM Poczobutt, K Yanagisawa, K Yang, L Cheng, M Haag, M Hassanein, M Hassanein, M Murphy, MJ Wakelam, MR Wenk, P Brites, R Angelis de, RA Murphy, RA Murphy, RE Smith, RL Keith, RT Sreseli, S Cedres, Srinivasarao Ravipati, WJ Scott, X Gao, X Zeng, Y Guo, YY Tyurina, ZA Fernandis   +40 more
core   +1 more source

Long noncoding nature brain-derived neurotrophic factor antisense is associated with poor prognosis and functional regulation in non–small cell lung caner

Tumor Biology, 2017
In this study, we evaluated the prognostic potential and functional regulation of human nature antisense, brain-derived neurotrophic factor antisense, in non–small cell lung cancer.
MingJing Shen, Zhonghua Xu, Kanqiu Jiang, Weihua Xu, Yongbin Chen, ZhongHeng Xu   +5 more
doaj   +1 more source

Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer. [PDF]

, 2016
Dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) is a member of dual-specificity kinase family, which could phosphorylate both Ser/Thr and Tyr substrates. The role of DYRK2 in human cancer remains controversial.
Chu, Zhonghua, Hu, Kaishun, Koeffler, H Phillip, Li, Yu, Tian, Huan, Wu, Wenjing, Yan, Haiyan, Yin, Dong   +7 more
core   +6 more sources